These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33010325)

  • 1. Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial.
    Niemeyer-van der Kolk T; Buters TP; Krouwels L; Boltjes J; de Kam ML; van der Wall H; van Alewijk DCJG; van den Munckhof EHA; Becker MJ; Feiss G; Florencia EF; Prens EP; Moerland M; Burggraaf J; Rissmann R; van Doorn MBA
    J Am Acad Dermatol; 2022 Apr; 86(4):854-862. PubMed ID: 33010325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial.
    Niemeyer-van der Kolk T; van der Wall H; Hogendoorn GK; Rijneveld R; Luijten S; van Alewijk DCJG; van den Munckhof EHA; de Kam ML; Feiss GL; Prens EP; Burggraaf J; Rissmann R; van Doorn MBA
    Clin Transl Sci; 2020 Sep; 13(5):994-1003. PubMed ID: 32315497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomes encapsulating novel antimicrobial peptide Omiganan: Characterization and its pharmacodynamic evaluation in atopic dermatitis and psoriasis mice model.
    Javia A; Misra A; Thakkar H
    Int J Pharm; 2022 Aug; 624():122045. PubMed ID: 35878872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial.
    Rousel J; Saghari M; Pagan L; Nădăban A; Gambrah T; Theelen B; de Kam ML; Haakman J; van der Wall HEC; Feiss GL; Niemeyer-van der Kolk T; Burggraaf J; Bouwstra JA; Rissmann R; van Doorn MBA
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the Cutaneous Microbiota in Atopic Dermatitis by Coal Tar via AHR-Dependent Induction of Antimicrobial Peptides.
    Smits JPH; Ederveen THA; Rikken G; van den Brink NJM; van Vlijmen-Willems IMJJ; Boekhorst J; Kamsteeg M; Schalkwijk J; van Hijum SAFT; Zeeuwen PLJM; van den Bogaard EH
    J Invest Dermatol; 2020 Feb; 140(2):415-424.e10. PubMed ID: 31344386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleach baths enhance skin barrier, reduce itch but do not normalize skin dysbiosis in atopic dermatitis.
    Stolarczyk A; Perez-Nazario N; Knowlden SA; Chinchilli E; Grier A; Paller A; Gill SR; De Benedetto A; Yoshida T; Beck LA
    Arch Dermatol Res; 2023 Dec; 315(10):2883-2892. PubMed ID: 37755506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: Analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.
    Beck LA; Bieber T; Weidinger S; Tauber M; Saeki H; Irvine AD; Eichenfield LF; Werfel T; Arlert P; Jiang L; Røpke M; Paller AS
    J Am Acad Dermatol; 2023 Apr; 88(4):816-823. PubMed ID: 36473633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin dysbiosis in the microbiome in atopic dermatitis is site-specific and involves bacteria, fungus and virus.
    Bjerre RD; Holm JB; Palleja A; Sølberg J; Skov L; Johansen JD
    BMC Microbiol; 2021 Sep; 21(1):256. PubMed ID: 34551705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial.
    Gong JQ; Lin L; Lin T; Hao F; Zeng FQ; Bi ZG; Yi D; Zhao B
    Br J Dermatol; 2006 Oct; 155(4):680-7. PubMed ID: 16965415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobials from human skin commensal bacteria protect against
    Nakatsuji T; Chen TH; Narala S; Chun KA; Two AM; Yun T; Shafiq F; Kotol PF; Bouslimani A; Melnik AV; Latif H; Kim JN; Lockhart A; Artis K; David G; Taylor P; Streib J; Dorrestein PC; Grier A; Gill SR; Zengler K; Hata TR; Leung DY; Gallo RL
    Sci Transl Med; 2017 Feb; 9(378):. PubMed ID: 28228596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbial derived antimicrobial peptides as potential therapeutics in atopic dermatitis.
    Joshi AA; Vocanson M; Nicolas JF; Wolf P; Patra V
    Front Immunol; 2023; 14():1125635. PubMed ID: 36761743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of skin dysbiosis in atopic dermatitis.
    Braun C; Patra V; Lina G; Nicolas JF; Vocanson M; Nosbaum A
    Eur J Dermatol; 2022 Jul; 32(4):439-444. PubMed ID: 36301755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models.
    Rubinchik E; Dugourd D; Algara T; Pasetka C; Friedland HD
    Int J Antimicrob Agents; 2009 Nov; 34(5):457-61. PubMed ID: 19524411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical ozone therapy restores microbiome diversity in atopic dermatitis.
    Zeng J; Dou J; Gao L; Xiang Y; Huang J; Ding S; Chen J; Zeng Q; Luo Z; Tan W; Lu J
    Int Immunopharmacol; 2020 Mar; 80():106191. PubMed ID: 31986325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sodium hypochlorite (bleach) baths to reduce Staphylococcus aureus colonization in childhood onset moderate-to-severe eczema: A randomized, placebo-controlled cross-over trial.
    Hon KL; Tsang YC; Lee VW; Pong NH; Ha G; Lee ST; Chow CM; Leung TF
    J Dermatolog Treat; 2016; 27(2):156-62. PubMed ID: 26270469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.
    Weiss A; Delavenne E; Matias C; Lagler H; Simon D; Li P; Hansen JU; Dos Santos TP; Jana B; Priemel P; Bangert C; Bauer M; Eberl S; Nussbaumer-Pröll A; Anne Österreicher Z; Matzneller P; Quint T; Weber M; Nielsen HM; Rades T; Johansen HK; Westh H; Kim W; Mylonakis E; Friis C; Guardabassi L; Pace J; Lundberg CV; M'Zali F; Butty P; Sørensen N; Nielsen HB; Toft-Kehler R; Guttman-Yassky E; Stingl G; Zeitlinger M; Sommer M
    Clin Transl Med; 2022 May; 12(5):e790. PubMed ID: 35522900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical S. aureus - Targeting Endolysin Significantly Improves Symptoms and QoL in Individuals With Atopic Dermatitis.
    Moreau M; Seité S; Aguilar L; Da Cruz O; Puech J; Frieling J; Demessant A
    J Drugs Dermatol; 2021 Dec; 20(12):1323-1328. PubMed ID: 34898160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skin pH-dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity.
    Hülpüsch C; Tremmel K; Hammel G; Bhattacharyya M; de Tomassi A; Nussbaumer T; Neumann AU; Reiger M; Traidl-Hoffmann C
    Allergy; 2020 Nov; 75(11):2888-2898. PubMed ID: 32562575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glyoxal-induced exacerbation of pruritus and dermatitis is associated with staphylococcus aureus colonization in the skin of a rat model of atopic dermatitis.
    Han RT; Kim HY; Ryu H; Jang W; Cha SH; Kim HY; Lee J; Back SK; Kim HJ; Na HS
    J Dermatol Sci; 2018 Jun; 90(3):276-283. PubMed ID: 29496360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapies for atopic dermatitis: Additional treatment classes.
    Vakharia PP; Silverberg JI
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S76-S83. PubMed ID: 29248520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.